Targeting HER3 – a little wave of drug development that’s about to get a lot bigger
SugarCone Biotech
JULY 6, 2025
Reporting in Nature Reviews Drug Discovery, @AsherMullard noted that Merus must provide the FDA with confirmatory evidence of benefit in both NSCLC and pancreatic adenocarcinoma in order to achieve full approval and that analysts predict annual sales of around $180 million by 2030 per consensus forecast via Cortellis.
Let's personalize your content